Page 27 - Read Online

Mathieu et al. Metab Target Organ Damage 2022;2:15 https://dx.doi.org/10.20517/mtod.2022.16 Page 9 of 11

Copyright
© The Author(s) 2022

REFERENCES
1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-9. DOI
PubMed
2. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986;314:1360-8. DOI PubMed
3. Atkinson MA, Bluestone JA, Eisenbarth GS, et al. How does type 1 diabetes develop?: the notion of homicide or β-cell suicide
revisited. Diabetes 2011;60:1370-9. DOI PubMed PMC
4. Bakay M, Pandey R, Grant SFA, Hakonarson H. The genetic contribution to type 1 diabetes. Curr Diab Rep 2019;19:116. DOI
PubMed
5. Santin I, Eizirik DL. Candidate genes for type 1 diabetes modulate pancreatic islet inflammation and β-cell apoptosis. Diabetes Obes
Metab 2013;15 Suppl 3:71-81. DOI PubMed
6. Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet 2016;387:2331-9. DOI PubMed
7. Milluzzo A, Falorni A, Brozzetti A, et al. Risk for coexistent autoimmune diseases in familial and sporadic type 1 diabetes is related to
age at diabetes onset. Endocr Pract 2021;27:110-7. DOI PubMed
8. Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes
2017;66:241-55. DOI PubMed PMC
9. Winkler C, Haupt F, Heigermoser M, et al; GPPAD Study Group. Identification of infants with increased type 1 diabetes genetic risk
for enrollment into Primary Prevention Trials-GPPAD-02 study design and first results. Pediatr Diabetes 2019;20:720-7. DOI
PubMed PMC
10. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children.
JAMA 2013;309:2473-9. DOI PubMed PMC
11. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care 2015;38:989-96. DOI PubMed
12. Pugliese A. Insulitis in the pathogenesis of type 1 diabetes. Pediatr Diabetes 2016;17 Suppl 22:31-6. DOI PubMed PMC
13. De Leenheer E, Wong FS. Adoptive transfer of autoimmune diabetes using immunodeficient Nonobese Diabetic (NOD) mice. In:
Gillespie KM, editor. Type-1 Diabetes. New York: Springer; 2016. pp. 135-40.
14. Burrack AL, Martinov T, Fife BT. T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1
diabetes. Front Endocrinol (Lausanne) 2017;8:343. DOI PubMed PMC
15. Virostko J, Williams J, Hilmes M, et al. Pancreas volume declines during the first year after diagnosis of type 1 diabetes and exhibits
altered diffusion at disease onset. Diabetes Care 2019;42:248-57. DOI PubMed PMC
16. Campbell-Thompson ML, Filipp SL, Grajo JR, et al. Relative pancreas volume is reduced in first-degree relatives of patients with type
1 diabetes. Diabetes Care 2019;42:281-7. DOI PubMed PMC
17. Wasserfall C, Nick HS, Campbell-Thompson M, et al. Persistence of pancreatic insulin mRNA expression and proinsulin protein in
type 1 diabetes pancreata. Cell Metab 2017;26:568-575.e3. DOI PubMed PMC
18. Rodriguez-Calvo T, Zapardiel-Gonzalo J, Amirian N, et al. Increase in pancreatic proinsulin and preservation of β-cell mass in
autoantibody-positive donors prior to type 1 diabetes onset. Diabetes 2017;66:1334-45. DOI PubMed PMC
19. Eizirik DL, Miani M, Cardozo AK. Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic
islet inflammation. Diabetologia 2013;56:234-41. DOI PubMed
20. Thomaidou S, Kracht MJL, van der Slik A, et al. β-cell stress shapes CTL immune recognition of preproinsulin signal peptide by
posttranscriptional regulation of endoplasmic reticulum aminopeptidase 1. Diabetes 2020;69:670-80. DOI PubMed
21. Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, Eizirik DL. IL-1beta and IFN-gamma induce the expression of diverse
chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 2003;46:255-66.
DOI PubMed
22. Richardson SJ, Rodriguez-Calvo T, Gerling IC, et al. Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1
diabetes. Diabetologia 2016;59:2448-58. DOI PubMed PMC
23. Peters L, Posgai A, Brusko TM. Islet-immune interactions in type 1 diabetes: the nexus of beta cell destruction. Clin Exp Immunol
2019;198:326-40. DOI PubMed PMC
24. Kracht MJL, Zaldumbide A, Roep BO. Neoantigens and microenvironment in type 1 diabetes: lessons from antitumor immunity.
Trends Endocrinol Metab 2016;27:353-62. DOI PubMed
25. Roep BO, Kracht MJ, van Lummel M, Zaldumbide A. A roadmap of the generation of neoantigens as targets of the immune system in
type 1 diabetes. Curr Opin Immunol 2016;43:67-73. DOI PubMed
26. Martens PJ, Gysemans C, Mathieu C. 100 YEARS OF INSULIN: arresting or curing type 1 diabetes: an elusive goal, but closing the
gap. J Endocrinol 2021;249:T1-T11. DOI PubMed
27. Primavera M, Giannini C, Chiarelli F. Prediction and prevention of type 1 diabetes. Front Endocrinol (Lausanne) 2020;11:248. DOI